Literature DB >> 8526862

Purification and characterization of the human type 1 Ins(1,4,5)P3 receptor from platelets and comparison with receptor subtypes in other normal and transformed blood cells.

F O'Rourke1, E Matthews, M B Feinstein.   

Abstract

We report the first purification of a native human form of the Ins(1,4,5)P3 (InsP3) receptor. This receptor, isolated from platelets, has an apparent molecular mass on SDS/PAGE of 252 kDa and is chromatographed by gel filtration as an oligomer of about 1 x 10(6) kDa. [3H]InsP3 bound to a single class of sites on the purified receptor protein with a Kd of 27 nM and a Bmax. of 2.2 nmol/mg of protein. The platelet InsP3 receptor, like the rodent cerebellar receptors, was identified immunochemically as a type 1 receptor, but unlike its brain counterparts bound poorly to concanavalin A and other lectins and was not significantly phosphorylated by protein kinase A. All cultured megakaryocytic leukaemia cell lines (e.g. Dami, CHRF-288 and Meg-01) and HEL cells were also immunopositive for type 1 receptor, which was substantially increased in some cases by DMSO or phorbol 12-myristate 13-acetate (PMA) which induce further megakaryocytic differentiation. Normal mixed lymphocyte and granulocyte fractions and an enriched T-cell fraction from human blood had measurable InsP3-binding activity, but no detectable type 1 protein. In contrast, Jurkat E6-1 (T-cell lymphoma) cells and the transformed B-cell line RPMI 8392 were immunopositive for type 1 receptor. HL-60 (human promyelocytic leukaemia) cells had no detectable type 1 receptor unless they were stimulated to differentiate along monocyte/macrophage lines by PMA. We conclude that: (1) of the major normal blood cells only platelets contain type 1 InsP3 receptors; (2) some neoplastic transformed blood cell lines also express type 1 receptors, in contrast to their normal counterparts; and (3) increased levels of type 1 InsP3 receptor are induced in some transformed cells under conditions that favour their further terminal differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526862      PMCID: PMC1136290          DOI: 10.1042/bj3120499

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  19 in total

1.  Solubilization, purification, and characterization of an inositol trisphosphate receptor.

Authors:  S Supattapone; P F Worley; J M Baraban; S H Snyder
Journal:  J Biol Chem       Date:  1988-01-25       Impact factor: 5.157

2.  Purification and characterization of the inositol 1,4,5- trisphosphate receptor protein from rat vas deferens.

Authors:  R J Mourey; A Verma; S Supattapone; S H Snyder
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Structure and expression of the rat inositol 1,4,5-trisphosphate receptor.

Authors:  G A Mignery; C L Newton; B T Archer; T C Südhof
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

4.  Primary structure and functional expression of the inositol 1,4,5-trisphosphate-binding protein P400.

Authors:  T Furuichi; S Yoshikawa; A Miyawaki; K Wada; N Maeda; K Mikoshiba
Journal:  Nature       Date:  1989-11-02       Impact factor: 49.962

5.  Release of Ca2+ by inositol 1,4,5-trisphosphate in platelet membrane vesicles is not dependent on cyclic AMP-dependent protein kinase.

Authors:  F O'Rourke; G B Zavoico; M B Feinstein
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

6.  The inositol 1,4,5-trisphosphate receptor binding sites of platelet membranes. pH-dependency, inhibition by polymeric sulphates, and the possible presence of arginine at the binding site.

Authors:  F O'Rourke; M B Feinstein
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

7.  Phosphorylation of P400 protein by cyclic AMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase II.

Authors:  H Yamamoto; N Maeda; M Niinobe; E Miyamoto; K Mikoshiba
Journal:  J Neurochem       Date:  1989-09       Impact factor: 5.372

8.  Structural and functional characterization of inositol 1,4,5-trisphosphate receptor channel from mouse cerebellum.

Authors:  N Maeda; T Kawasaki; S Nakade; N Yokota; T Taguchi; M Kasai; K Mikoshiba
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

9.  The human type 1 inositol 1,4,5-trisphosphate receptor from T lymphocytes. Structure, localization, and tyrosine phosphorylation.

Authors:  D J Harnick; T Jayaraman; Y Ma; P Mulieri; L O Go; A R Marks
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

10.  Cyclic AMP-dependent protein kinase does not increase calcium transport in platelet microsomes.

Authors:  G C White; D W Barton; T E White; T H Fischer
Journal:  Thromb Res       Date:  1989-12-01       Impact factor: 3.944

View more
  5 in total

1.  Dual regulation of calcium mobilization by inositol 1,4, 5-trisphosphate in a living cell.

Authors:  S Tertyshnikova; A Fein
Journal:  J Gen Physiol       Date:  2000-04       Impact factor: 4.086

2.  Cloning of human Ca2+ homoeostasis endoplasmic reticulum protein (CHERP): regulated expression of antisense cDNA depletes CHERP, inhibits intracellular Ca2+ mobilization and decreases cell proliferation.

Authors:  J M Laplante; F O'Rourke; X Lu; A Fein; A Olsen; M B Feinstein
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

3.  Biogenesis of endoplasmic reticulum proteins involved in Ca2+ signalling during megakaryocytic differentiation: an in vitro study.

Authors:  C Lacabaratz-Porret; S Launay; E Corvazier; R Bredoux; B Papp; J Enouf
Journal:  Biochem J       Date:  2000-09-15       Impact factor: 3.857

4.  Inositol 1,4,5-trisphosphate receptor subtypes differentially recognize regioisomers of D-myo-inositol 1,4,5-trisphosphate.

Authors:  M Hirata; H Takeuchi; A M Riley; S J Mills; Y Watanabe; B V Potter
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

5.  Isolation of InsP4 and InsP6 binding proteins from human platelets: InsP4 promotes Ca2+ efflux from inside-out plasma membrane vesicles containing 104 kDa GAP1IP4BP protein.

Authors:  F O'Rourke; E Matthews; M B Feinstein
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.